Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Gross Margin (2023 - 2025)

Historic Gross Margin for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to 99.51%.

  • Immunocore Holdings' Gross Margin rose 600.0% to 99.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.29%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 99.12% for FY2024, which is 4600.0% down from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Gross Margin is 99.51%, which was up 600.0% from 98.94% recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Gross Margin registered a high of 99.89% during Q2 2022, and its lowest value of 97.74% during Q2 2024.
  • For the 4-year period, Immunocore Holdings' Gross Margin averaged around 99.32%, with its median value being 99.51% (2025).
  • As far as peak fluctuations go, Immunocore Holdings' Gross Margin crashed by -16800bps in 2024, and later skyrocketed by 12000bps in 2025.
  • Over the past 4 years, Immunocore Holdings' Gross Margin (Quarter) stood at 98.96% in 2022, then increased by 1bps to 99.71% in 2023, then dropped by 0bps to 99.61% in 2024, then decreased by 0bps to 99.51% in 2025.
  • Its Gross Margin was 99.51% in Q3 2025, compared to 98.94% in Q2 2025 and 99.11% in Q1 2025.